No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
DENMARK —Danish dermatology specialist, LEO Pharma, has announced a strategic partnership with the Irish firm, ICON, to focus on clinical trial execution. With a significant presence in the dermatology products…
Read More
DENMARK — Novo Nordisk has announced that Jeppe Christiansen will not stand for re-election as member of the Board at the AGM to be held on 23 March 2023. The…
Read More
DENMARK — Bavarian Nordic, a Danish vaccine maker, has announced that it will acquire Emergent Biosolutions Inc.’s travel-health business for a total of US$380 million. The acquisition will expand Bavarian…
Read More
DENMARK —Novo Nordisk has expanded its collaboration with Amalgam Rx, a US-based company to support the commercialization of Dose Check, a digital insulin initiation and titration app. Dose Check digital…
Read More
DENMARK — Danish pharmaceutical company Novo Nordisk is set to invest 5.4 billion Danish kroner (US$743.6 million) in expanding its facilities in Bagsvaerd, Denmark, which will include construction of a…
Read More
DENMARK — Novo Nordisk has signed a collaboration agreement with Biocorp for the initial commercialization of Mallya, initially in Japan. Mallya connects directly to Novo Nordisk FlexTouch insulin pens, allowing…
Read More
DENMARK – Novo Nordisk has published topline results from six Phase 3a clinical trials in the ONWARDS program of once-weekly insulin icodec in diabetics. Insulin icodec is a novel once-weekly…
Read More
DENMARK – Denmark’s Novo Nordisk Foundation has pledged US$200 million (£176m) to develop what it says will be the first quantum computer dedicated to life sciences research and the green…
Read More
DENMARK – Nine ventures and two projects have become the latest addition to the BioInnovation Institute’s (BII) Venture Lab acceleration program for early-stage companies. BII is an international commercial non-profit…
Read More
DENMARK- Novo Nordisk has entered into a legally binding agreement to acquire clinical-stage biopharmaceutical firm Forma Therapeutics in a deal valued at US$1.1 billion (or US$20 per share). Forma Therapeutics…
Read More